|
| 37470150 | Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia. | Haematologica | 2024 |
| 37984809 | A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia. | Cytometry A | 2024 |
| 36318439 | Resistance to targeted therapies in acute myeloid leukemia. | Clin Exp Metastasis | 2023 |
| 37756525 | Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. | Blood | 2023 |
| 37799345 | Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. | Hemasphere | 2023 |
| 38066915 | Understanding differential technologies for detection of MRD and how to incorporate into clinical practice. | Hematology Am Soc Hematol Educ Program | 2023 |
| 37587502 | Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. | J Hematol Oncol | 2023 |
| 37587260 | Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia. | Leukemia | 2023 |
| 38049829 | Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. | Mol Cancer | 2023 |
| 37684299 | Randomized phase-III study of low-dose cytarabine and etoposideâ¿¿+â¿¿/- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. | Sci Rep | 2023 |
| 37568726 | MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML. | Cancers (Basel) | 2023 |
| 37766974 | Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus <i>MYNRL15</i>. | iScience | 2023 |
| 37671649 | Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. | Am J Hematol | 2023 |
| 37024521 | In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. | Leukemia | 2023 |
| 37187198 | Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. | Lancet Haematol | 2023 |
| 37311155 | Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. | Am Soc Clin Oncol Educ Book | 2023 |
| 37041215 | Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Bone Marrow Transplant | 2023 |
| 37170899 | Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review. | Future Oncol | 2023 |
| 37101762 | Palbociclib in Acute Leukemias With <i>KMT2A</i>-rearrangement: Results of AMLSG 23-14 Trial. | Hemasphere | 2023 |
| 37033919 | Non-viral <i>TRAC</i>-knocked-in CD19<sup>KI</sup>CAR-T and gp350<sup>KI</sup>CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: <i>In vivo</i> cellular dynamics and potency. | Front Immunol | 2023 |
| 37096215 | Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria. | Hemasphere | 2023 |
| 36576532 | Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. | Ann Hematol | 2023 |
| 36601981 | Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER). | Haematologica | 2023 |
| 36940410 | Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. | Blood | 2023 |
| 36566048 | A new player in IDH1 mutated myeloid neoplasias. | Lancet Haematol | 2023 |
| 36823395 | Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. | Leukemia | 2023 |
| 36892565 | Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax. | Cancer Discov | 2023 |
| 34316017 | Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. | Leukemia | 2022 |
| 35443108 | Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid Leukemia. | N Engl J Med | 2022 |
| 35839275 | Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. | Blood Cancer Discov | 2022 |
| 35724849 | Increased Late Noncardiac Nonrelapse Mortality in Patients with Atrial Fibrillation Diagnosed During Their Hospital Stay for Allogeneic Stem Cell Transplantation. | Transplant Cell Ther | 2022 |
| 35486475 | Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. | Blood Adv | 2022 |
| 35875134 | Clonal Evolution at First Sight: A Combined Visualization of Diverse Diagnostic Methods Improves Understanding of Leukemic Progression. | Front Oncol | 2022 |
| 36142824 | Healthy-like CD4<sup>+</sup> Regulatory and CD4<sup>+</sup> Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion. | Int J Mol Sci | 2022 |
| 36204690 | High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis. | Hemasphere | 2022 |
| 35922444 | Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. | Leukemia | 2022 |
| 35917453 | Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. | Blood | 2022 |
| 35974101 | Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. | Leukemia | 2022 |
| 35272130 | Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. | ESMO Open | 2022 |
| 34726055 | A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. | J Med Chem | 2022 |
| 32203138 | Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. | Leukemia | 2021 |
| 33598693 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. | Blood | 2021 |
| 33740113 | Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. | Ann Hematol | 2021 |
| 33486841 | Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype. | Genes Chromosomes Cancer | 2021 |
| 33512436 | Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. | Blood | 2021 |
| 33510405 | Germline variants drive myelodysplastic syndrome in young adults. | Leukemia | 2021 |
| 33759009 | Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis? | Clin Exp Metastasis | 2021 |
| 33564192 | Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. | Nat Med | 2021 |
| 33755092 | A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. | Blood Adv | 2021 |
| 33725366 | Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. | Am J Hematol | 2021 |